Last reviewed · How we verify
NCT03894085
Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging （fMRI） Study With Paroxetine Treatment
NA trial testing Paroxetine in Anxiety Disorder in 150 participants. Completed in 31 December 2022.
31 December 2022
Quick facts
| Lead sponsor | Central South University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 30 May 2019 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Paroxetine — full drug profile →
Conditions studied
- Anxiety Disorder — all drugs for Anxiety Disorder →
- Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
Sponsor
Central South University
Who can join
Adults 18 to 56, any sex, with Anxiety Disorder or Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore reliable neuroimaging biomarkers for anxiety disorder and OCD,and whether there are shared imaging biomarkers between different subtypes of anxiety disorder and OCD, the investigators included30 drug-naive general anxiety disorder (GAD),30 drug-naïve panic disorder(PD),30 drug-naïve social anxiety disorder,30 drug-naive.obsessive-compulsive disorder patients and 30 healthy controls by using a combination of cross-section and longitudinal study designs, including a longitudinal study in patients with anxiety disorder and OCD with 4 weeks of selective serotonin reuptake inhibitor (SSRI) paroxetine treatment. The investigators will also evaluate the severity of symptom, social function, cognitive function and treatment response.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Network-based stage-specific drug repurposing for Alzheimer's disease.
Savva K, Zachariou M, Bourdakou MM, Dietis N, et al · · 2022 · cited 24× · PMID 35386099 · DOI 10.1016/j.csbj.2022.03.013 -
Disrupted functional connectivity associated with cognitive impairment in generalized anxiety disorder (GAD) and comorbid GAD and depression: a follow-up fMRI study.
Han Y, Yan H, Shan X, Li H, et al · · 2023 · cited 10× · PMID 37935477 · DOI 10.1503/jpn.230091 -
Breaking the Fear Barrier: Aberrant Activity of Fear Networks as a Prognostic Biomarker in Patients with Panic Disorder Normalized by Pharmacotherapy.
Yan H, Han Y, Shan X, Li H, et al · · 2023 · cited 2× · PMID 37760861 · DOI 10.3390/biomedicines11092420 -
Decoding the striatum of drug-naive patients with obsessive-compulsive disorder: a transcriptome and longitudinal functional magnetic resonance imaging study.
Han Y, Yan H, Shan X, Li H, et al · · 2025 · PMID 40721576 · DOI 10.1038/s41398-025-03475-4
Verify or expand the search:
- PubMed search for NCT03894085
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Paroxetine
Trials testing the same drug.
- NCT06763484 — Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause · Phase 2 · completed
- NCT06232109 — Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects · Phase 1 · completed
- NCT06231745 — Paroxetine Safety and Efficacy in Rheumatoid Arthritis · Phase 3 · recruiting
- NCT06049797 — A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats · active not recruiting
- NCT06065735 — Concentration-QT Study of Paroxetine in Healthy Adults · Phase 1 · completed
Other recruiting trials for Anxiety Disorder
Currently open trials in the same condition.
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT07221409 — Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment · NA · recruiting
- NCT07045818 — DLPFC and Sympathetic Reactivity in RPL With Anxiety · recruiting
- NCT05232032 — Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation · Phase 2 · recruiting
- NCT06333925 — Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study · NA · active not recruiting
Other Central South University trials
Trials by the same sponsor.
- NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
- NCT07446478 — TIS for Improving Cognitive Impairment Associated With Schizophrenia · NA · not yet recruiting
- NCT07045142 — Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients · Phase 3 · recruiting
- NCT07066813 — Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces · recruiting
- NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03894085 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central South University
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03894085.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing